A citation-based method for searching scientific literature

Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
Times Cited: 788



Krishnansu S Tewari, Robert A Burger, Danielle Enserro, Barbara M Norquist, Elizabeth M Swisher, Mark F Brady, Michael A Bookman, Gini F Fleming, Helen Huang, Howard D Homesley, Jeffrey M Fowler, Benjamin E Greer, Matthew Boente, Sharon X Liang, Chenglin Ye, Carlos Bais, Leslie M Randall, John K Chan, J Stuart Ferriss, Robert L Coleman, Carol Aghajanian, Thomas J Herzog, Philip J DiSaia, Larry J Copeland, Robert S Mannel, Michael J Birrer, Bradley J Monk. J Clin Oncol 2019
Times Cited: 119




List of shared articles



Times cited

The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
Shiru Liu, Lawrence Kasherman, Rouhi Fazelzad, Lisa Wang, Genevieve Bouchard-Fortier, Stephanie Lheureux, Monika K Krzyzanowska. Gynecol Oncol 2021
1

Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer.
Olivia Le Saux, Hélène Vanacker, Fatma Guermazi, Mélodie Carbonnaux, Clémence Roméo, Louis Larrouquère, Olivier Trédan, Isabelle Ray-Coquard. Future Oncol 2021
0

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci, Rossella Lauria,[...]. Int J Gynecol Cancer 2021
3

The impact of body composition on treatment in ovarian cancer: a current insight.
Veronica McSharry, Kate Glennon, Amy Mullee, Donal Brennan. Expert Rev Clin Pharmacol 2021
0

Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Angeles Alvarez Secord, David M O'Malley, Anil K Sood, Shannon N Westin, Joyce F Liu. Gynecol Oncol 2021
0

The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment.
Mark A Eckert, Carlos Orozco, Jason Xiao, Melissa Javellana, Ernst Lengyel. Cancers (Basel) 2021
0

Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer.
Paola Todeschini, Elisa Salviato, Chiara Romani, Vittoria Raimondi, Francesco Ciccarese, Federico Ferrari, Germana Tognon, Sergio Marchini, Maurizio D'Incalci, Laura Zanotti,[...]. Cancers (Basel) 2021
0

Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052).
Se Ik Kim, Jeong-Won Lee, Kidong Kim, Maria Lee, Jigeun Yoo, Min Chul Choi, Suhyun Hwangbo, Young Hwa Kwak, Jong-Min Lee, So-Jin Shin,[...]. J Gynecol Oncol 2021
0

Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.
Jonathan S Berek, Malte Renz, Sean Kehoe, Lalit Kumar, Michael Friedlander. Int J Gynaecol Obstet 2021
0

Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Katherine C Kurnit, Gini F Fleming, Ernst Lengyel. Obstet Gynecol 2021
12

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
J A Ledermann, A C Embleton-Thirsk, T J Perren, G C Jayson, G J S Rustin, S B Kaye, H Hirte, A Oza, M Vaughan, M Friedlander,[...]. ESMO Open 2021
1

Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer.
Angela Cho, Jeong-Yeol Park, Shin-Wha Lee, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim. Arch Gynecol Obstet 2021
0

Bevacizumab in advanced endometrial cancer.
Maria M Rubinstein, Shannan Dickinson, Priyanka Narayan, Qin Zhou, Alexia Iasonos, Weining Ma, Yulia Lakhman, Vicky Makker. Gynecol Oncol 2021
1

A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA.
Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys. Acta Clin Belg 2021
0

AIM2 Inflammasome in Tumor Cells as a Biomarker for Predicting the Treatment Response to Antiangiogenic Therapy in Epithelial Ovarian Cancer Patients.
Po-Chao Hsu, Tai-Kuang Chao, Yu-Ching Chou, Mu-Hsien Yu, Yu-Chi Wang, Yi-Hsin Lin, Yi-Liang Lee, Li-Chun Liu, Cheng-Chang Chang. J Clin Med 2021
0

The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer.
Alexander D Murphy, Robert D Morgan, Andrew R Clamp, Gordon C Jayson. Br J Cancer 2021
0

Latest clinical evidence of maintenance therapy in ovarian cancer.
Christine S Walsh. Curr Opin Obstet Gynecol 2020
12

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Josep Garcia, Herbert I Hurwitz, Alan B Sandler, David Miles, Robert L Coleman, Regula Deurloo, Olivier L Chinot. Cancer Treat Rev 2020
119